TE
Schedule 13G filing
Trails Edge Capital Partners, LP disclosed a 5.2% stake in AVTX
Trails Edge Capital Partners, LP reported owning 5.2% of Avalo Therapeutics, Inc. (AVTX) (2,803,761 shares) in a Schedule 13G filed Oct 29, 2026.
A 13G is a passive stake: the holder does not plan to push for changes.
- Disclosed
- Oct 29, 2026
- Source
- Schedule 13G
More AVTX insider and Congress trades
From a public Schedule 13G, linked above. Not investment advice, and not a recommendation to buy or sell.